Update on Vitamin E and Its Potential Role in Preventing or Treating Bronchopulmonary Dysplasia
- PMID: 29514147
- PMCID: PMC5980725
- DOI: 10.1159/000487388
Update on Vitamin E and Its Potential Role in Preventing or Treating Bronchopulmonary Dysplasia
Abstract
Vitamin E is obtained only through the diet and has a number of important biological activities, including functioning as an antioxidant. Evidence that free radicals may contribute to pathological processes such as bronchopulmonary dysplasia (BPD), a disease of prematurity associated with increased lung injury, inflammation and oxidative stress, led to trials of the antioxidant vitamin E (α-tocopherol) to prevent BPD with variable results. These trials were all conducted at supraphysiologic doses and 2 of these trials utilized a formulation containing a potentially harmful excipient. Since 1991, when the last of these trials was conducted, both neonatal management strategies for minimizing oxygen and ventilator-related lung injury and our understanding of vitamin E isoforms in respiratory health have advanced substantially. It is now known that there are differences between the effects of vitamin E isoforms α-tocopherol and γ-tocopherol on the development of respiratory morbidity and inflammation. What is not known is whether improvements in physiologic concentrations of individual or combinations of vitamin E isoforms during pregnancy or following preterm birth might prevent or reduce BPD development. The answers to these questions require adequately powered studies targeting pregnant women at risk of preterm birth or their premature infants immediately following birth, especially in certain subgroups that are at increased risk of vitamin E deficiency (e.g., smokers). The objective of this review is to compile, update, and interpret what is known about vitamin E isoforms and BPD since these first studies were conducted, and suggest future research directions.
Keywords: Bronchopulmonary dysplasia; Chronic lung disease of prematurity; Oxidative stress; Tocopherol; Vitamin E; α-Tocopherol; γ-Tocopherol.
© 2018 S. Karger AG, Basel.
Conflict of interest statement
Figures
References
-
- Aschner J, Patrick S, Stark A, Lee S. The Scope and Organization of Neonatology: North American and Global Comparisons. Avery’s Neonatology: Pathophysiology and Management of the Newborn, LWW. (7) 2015
-
- Pryhuber G, Maitre N, Ballard R, Cifelli D, Davis S, Ellenberg J, Greenberg J, Kemp J, Mariani T, Panitch H, Ren C, Shaw P, Taussig L, Hamvas A. Prematurity and respiratory outcomes program (PROP): study protocol of a prospective multicenter study of respiratory outcomes of preterm infants in the United States. BMC Pediatr. 2015;15 - PMC - PubMed
-
- Higgins R, Jobe A, Koso-Thomas M, Bancalari E, Viscardi R, Hartert T, Ryan R, Kallapur S, Steinhorn R, Konduri G, Davis S, Thebaud B, Clyman R, Collaco J, Martin C, Woods J, Finer N, Raju T. Executive Summary of the Workshop on Bronchopulmonary Dysplasia The Journal of Pediatrics. J Pediatr. 2018 White Paper- In Press. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K24 AI077930/AI/NIAID NIH HHS/United States
- UG3 OD035517/OD/NIH HHS/United States
- UG3 OD023320/OD/NIH HHS/United States
- U01 AI131337/AI/NIAID NIH HHS/United States
- UG3 OD023288/OD/NIH HHS/United States
- U01 HL101456/HL/NHLBI NIH HHS/United States
- I01 BX000624/BX/BLRD VA/United States
- UG3 OD023282/OD/NIH HHS/United States
- T32 HL087738/HL/NHLBI NIH HHS/United States
- R01 HL105447/HL/NHLBI NIH HHS/United States
- UG3 OD035516/OD/NIH HHS/United States
- R01 HL129060/HL/NHLBI NIH HHS/United States
- U19 AI095227/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
